Affiliations: [a] Department of Radiotherapy, Zhongyi Northeast International Hospital Co., Ltd. Shenyang, China | [b] Department of Pulmonary and Critical Care Medicine, General Hospital of Northern Theater Command, Shenyang, China
Correspondence:
[*]
Corresponding author: Ying Gao, Department of Pulmonary and Critical Care Medicine, General Hospital of Northern Theater Command, No. 83,Wenhua Road, Shenhe District, Shenyang 110016, China. E-mail: Gaoyingshenyang12@outlook.com.
Note: [1] Contributed equally.
Abstract: BACKGROUND: non-small cell lung cancer (NSCLC) accounts for more than 80% of all lung cancer populations. Stereotactic radiotherapy (SBRT) is mainly suitable for early NSCLC patients who are not suitable for surgery or refuse surgery. OBJECTIVE: To analyze the effects of stereotactic radiotherapy (SBRT) plus immunotherapy for non-small cell lung cancer (NSCLC) patients on their immune status and survival quality. METHODS: NSCLC patients admitted to our hospital from 2019–2022 were divided into 61 cases in control group (SBRT) and 60 cases in observation group (SBRT plus immunotherapy) by the randomized numerical table method to compare the efficacy, the level of tumor markers in the serum, the level and activity of the immune cells in the peripheral blood and the Kahlil’s functional status (KPS) scores. RESULTS: The observation group had a higher efficacy rate than that of the control group (P< 0.05). There was no statistical difference between the two groups in serum tumor marker content, immune cell level and activity in peripheral blood and KPS score before treatment (P> 0.05). After treatment, serum tumor markers were lower than those in control group, and immune cell level, NK cell-related activity and KPS score were higher than those in control group (P< 0.05). CONCLUSION: SBRT plus immunotherapy can reduce the level of various tumor markers, improve the immune status and quality of survival for NSCLC patients.
